KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $96.3 million.

  • Xenon Pharmaceuticals' Operating Expenses rose 3075.63% to $96.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $348.3 million, marking a year-over-year increase of 3630.46%. This contributed to the annual value of $279.3 million for FY2024, which is 3048.02% up from last year.
  • Xenon Pharmaceuticals' Operating Expenses amounted to $96.3 million in Q3 2025, which was up 3075.63% from $94.2 million recorded in Q2 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Operating Expenses peaked at $96.3 million during Q3 2025, and registered a low of $20.4 million during Q1 2021.
  • Its 5-year average for Operating Expenses is $52.6 million, with a median of $53.7 million in 2023.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 8768.32% in 2023, then soared by 2036.66% in 2024.
  • Over the past 5 years, Xenon Pharmaceuticals' Operating Expenses (Quarter) stood at $28.6 million in 2021, then skyrocketed by 51.64% to $43.3 million in 2022, then rose by 23.92% to $53.7 million in 2023, then surged by 44.29% to $77.5 million in 2024, then rose by 24.34% to $96.3 million in 2025.
  • Its Operating Expenses stands at $96.3 million for Q3 2025, versus $94.2 million for Q2 2025 and $80.2 million for Q1 2025.